"Not all glucose lowering therapies are now equal. There has been a shift in the consensus towards patient-centered care where we match therapies to patient profiles, particularly around cardiovascular risk and cardiorenal protection, but also around hypoglycaemia and weight gain."
"Rather than adding treatments on top of each other, we should use smart combinations of therapies based on our understanding of that patient and the underlying pathophysiology." – Prof Melanie Davies
Biguanide class, oral tablet
To make sure your patients are optimally treated, guidelines recommend reassessing regularly (every 3–6 months) and modifying treatment when necessary.1
Still not under control?
Scroll down to see recommendations for other glucose-lowering medications when patients are not controlled on metformin.
To make sure your patients are optimally treated, guidelines recommend reassessing regularly (every 3–6 months) and modifying treatment when necessary.1
Still not under control?
Scroll down to see recommendations for other glucose-lowering medications when patients are not controlled on metformin.
Oral tablet or injection
*according to label indication
Oral tablet
*according to label indication
To make sure your patients are optimally treated, guidelines recommend reassessing regularly (every 3–6 months) and modifying treatment when necessary.1
No cardiovascular or kidney disease?
Scroll down to see recommendations for second-line therapy with other patient characteristics in mind
To make sure your patients are optimally treated, guidelines recommend reassessing regularly (every 3–6 months) and modifying treatment when necessary.1
No cardiovascular or kidney disease?
Scroll down to see recommendations for second-line therapy with other patient characteristics in mind
Oral tablet or injection
*according to label indication
Oral tablet
*according to label indication
Oral tablet
Oral tablet
Oral tablet
Davies MJ, D'Alessio DA, Fradkin J et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701.
Buse JB, Wexler D, Tsapas A et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43(2):487-493.
Mosenzon O, Alguwaihes A , Leon JLA et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021 Jul 27;20(1):154.